Axim Biotechnologies was mentioned in an article by US Market Buzz about their new non-psychotropic cannabinoid gum “CanChew“.
“Axim is taking on challenges from a biological standpoint, too. Since cannabinoids are destroyed in the hepatic system after they enter the GI tract, Axim is still trying to work out how to retain the therapeutic value through special formulations.
The company’s target launch date is 2017.”
